Initiation of HIV PrEP in Young Adults Rose in Recent Years
By Lori Solomon HealthDay Reporter
TUESDAY, June 3, 2025 -- Dispensing and initiation of HIV preexposure prophylaxis (PrEP) among young adults increased from 2016 through 2023, according to a study published online May 9 in the Journal of General Internal Medicine.
Nina E. Hill, M.D., from the University of Michigan in Ann Arbor, and colleagues examined recent trends in HIV PrEP among young adults (aged 18 to 25 years). The analysis included data from the IQVIA Longitudinal Prescription Database (roughly 1.45 million prescriptions from 2016 through 2023).
The researchers found that the quarterly PrEP dispensing rate increased sharply between 2016 and 2018, from 26.4 to 100.7 prescriptions per 100,000 people (quarterly percent change [QPC], 12.5 percent). Thereafter, the rate increased gradually to 208.4 prescriptions per 100,000 people in 2023 (QPC, 3.5 percent). A similar trend was seen for the quarterly PrEP initiation rate. Quarterly mean persistence decreased from 111.6 days in 2016 to 98.4 days in 2023 (QPC, −0.4 percent). Individuals aged 18 to 21 years had lower quarterly PrEP dispensing and initiation rates throughout the study period compared with those aged 22 to 25 years. In 2016, persistence was lower in these younger individuals, but the gap narrowed over time.
"Dispensing and initiation of PrEP among young adults is increasing, but treatment episodes are shortening," the authors write. "Efforts to promote retention in therapy are needed."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
ACP Issues Clinical Guideline for Statin Use in Persons With HIV
THURSDAY, May 29, 2025 -- In a clinical guideline issued by the American College of Physicians and published online May 27 in the Annals of Internal Medicine, recommendations are...
Exposure to Certain HIV Drugs May Significantly Lower Risk for Alzheimer Disease
TUESDAY, May 20, 2025 -- Exposure to nucleoside reverse transcriptase inhibitors (NRTIs), which treat HIV and hepatitis B and inhibit inflammasome activation, is associated with a...
Guidelines Updated for Nonoccupational Postexposure Prophylaxis for HIV
FRIDAY, May 9, 2025 -- Updated recommendations for antiretroviral nonoccupational postexposure prophylaxis (nPEP) for HIV have been published in the May 8 issue of the U.S...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.